Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-An effect probably mediated by direct platelet PPARγ activation

Greater reduction in platelet activity observed with rosiglitazone may be related to reduced oxidative stress and a possible direct PPARγ mediated effect on platelet function.